Dimitris Kardassis

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

St Segment Elevation Myocardial Infarction

Acute Coronary Syndrome

Induced Pluripotent Stem Cells

Top Venues

Journal of the American Heart Association

This page only lists publications with an associated author ORCID identifier.

Publications

Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)